Pharmaceutical compounds
This invention relates to compounds that are agonists of the muscarinic M 1 and M 4 receptor and which are useful in the treatment of diseases mediated by the muscarinic M 1 and/or M 4 receptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula (1): and salts thereof.
1. A compound of formula (1):
or a salt thereof.
2. The compound according to claim 1 , which is a compound of formula (2):
or a salt thereof.
3. A salt of the compound according to claim 1 .
4. A pharmaceutically acceptable salt of the compound according to claim 1 .
5. An acid addition salt of the compound according to claim 1 .
6. A hydrochloride salt of the compound according to claim 1 .
7. A monohydrochloride salt of the compound according to claim 1 .
8. The compound according to claim 1 , which is a compound of formula (2b):
9. The compound according to claim 1 , which is a compound of formula (2c):
10. A pharmaceutical composition comprising the compound according to claim 1 , or a salt thereof, and a pharmaceutically acceptable excipient.
11. A method of treating a disorder selected from a cognitive disorder and a psychotic disorder in a subject, comprising administering to the subject the compound of claim 1 , or a salt thereof.
12. The method according to claim 11 , wherein the disorder is Alzheimer's disease.
13. The method according to claim 11 , wherein the disorder is dementia with Lewy bodies.
14. The method according to claim 11 , wherein the disorder is schizophrenia.
15. A salt of the compound according to claim 2 .
16. A pharmaceutically acceptable salt of the compound according to claim 2 .
17. An acid addition salt of the compound according to claim 2 .
18. A hydrochloride salt of the compound according to claim 2 .
19. A monohydrochloride salt of the compound according to claim 2 .
20. A method of treating or lessening the severity of acute pain, chronic pain, neuropathic pain, or inflammatory pain in a subject, comprising administering to the subject the compound of claim 1 , or a salt thereof.
21. A pharmaceutical composition comprising the compound according to claim 2 , or a salt thereof, and a pharmaceutically acceptable excipient.
22. The method according to claim 11 , which is a method of treating a cognitive disorder.
23. The method according to claim 22 , wherein the cognitive disorder is a cognitive disorder associated with Alzheimer's disease.
24. A compound of formula (2):
25. A pharmaceutical composition comprising the compound according to claim 24 , and a pharmaceutically acceptable excipient.
26. A method of treating a disorder selected from a cognitive disorder and a psychotic disorder in a subject, comprising administering to the subject the compound according to claim 24 .
27. The method according to claim 26 , wherein the disorder is a cognitive disorder.
28. The method according to claim 27 , wherein the cognitive disorder is a cognitive disorder associated with Alzheimer's disease.
29. The method according to claim 26 , wherein the disorder is Alzheimer's disease.
30. The method according to claim 26 , wherein the disorder is dementia with Lewy bodies.
31. The method according to claim 26 , wherein the disorder is schizophrenia.